

Quantification of minimal disseminated disease by quantitative polymerase chain reaction and digital polymerase chain reaction for *NPM-ALK* as a prognostic factor in children with anaplastic large cell lymphoma

Christine Damm-Welk,^{1*} Nina Kutscher,¹ Martin Zimmermann,² Andishe Attarbaschi,³ Jutta Schieferstein,¹ Fabian Knörr,⁴ Ilske Oschlies,⁵ Wolfram Klapper⁵ and Wilhelm Woessmann^{1,4}

¹NHL-BFM Study Center, Department of Pediatric Hematology and Oncology, Giessen, Germany; ²Department of Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany; ³Department of Pediatric Hematology and Oncology, St. Anna Children's Hospital, Medical University of Vienna, Vienna, Austria; ⁴Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany and ⁵Institute of Pathology, Hematopathology Section and Lymph Node Registry, Kiel, Germany.

*Present address: Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

©2020 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2019.232314

Received: July 17, 2020.

Accepted: October 24, 2020.

Pre-published: October 24, 2020.

Correspondence: CHRISTINE DAMM-WELK - c.damm-welk@uke.de

WILHELM WOESSMANN - w.woessmann@uke.de

Supplementary Figure 1.

Outcome according to NPM-ALK copy numbers measured by RQ-PCR in bone marrow

Cumulative Incidence of relapse (A), event free survival (B) and overall survival (C) at three years according to a cut of off 10 normalized copy numbers NPM/ALK/104 copy numbers of ABL1 (NCN). BM=bone marrow

